Skip to main content
Fig. 3 | Breast Cancer Research

Fig. 3

From: Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study

Fig. 3

Benefit from 10 versus 5 y Tamoxifen is associated with increasing levels of BCI (H/I). Continuous risk curves based on RFI after 5- and 10 years of tamoxifen as a function of estrogen receptor (ER), progesterone receptor (PR), androgen receptor (AR), and Ki67 immunohistochemistry (IHC) expression, AR/ER IHC ratio and BCI (H/I) values

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us